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Abstract 
BACKGROUND: The interferon-free combination of the protease inhibitor ABT-450 with ritonavir 
(ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the nonnucleoside 
polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy 
against the hepatitis C virus (HCV) in patients with HCV genotype 1 infection. In this phase 3 
trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection 
and no cirrhosis. 
METHODS: In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned 
previously untreated patients with HCV genotype 1 infection, in a 3:1 ratio, to an active regimen 
consisting of a single-tablet coformulation of ABT-450/r-ombitasvir (at a once-daily dose of 150 
mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), and dasabuvir (250 mg twice 
daily) with ribavirin (in doses determined according to body weight) (group A) or matching 
placebos (group B). The patients received the study treatment during a 12-week double-blind 
period. The primary end point was sustained virologic response at 12 weeks after the end of 
treatment. The primary analysis compared the response rate in group A with the response rate 
(78%) in a historical control group of previously untreated patients without cirrhosis who received 
telaprevir with peginterferon and ribavirin. Adverse events occurring during the double-blind 
period were compared between group A and group B. 
RESULTS: A total of 631 patients received at least one dose of the study drugs. The rate of 
sustained virologic response in group A was 96.2% (95% confidence interval, 94.5 to 97.9), 
which was superior to the historical control rate. Virologic failure during treatment and relapse 
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after treatment occurred in 0.2% and 1.5%, respectively, of the patients in group A. The 
response rates in group A were 95.3% among patients with HCV genotype 1a infection and 
98.0% among those with HCV genotype 1b infection. The rate of discontinuation due to adverse 
events was 0.6% in each study group. Nausea, pruritus, insomnia, diarrhea, and asthenia 
occurred in significantly more patients in group A than in group B (P<0.05 for all comparisons). 
Reductions in the hemoglobin level were all of grade 1 or 2; reductions of grade 1 and 2 
occurred in 47.5% and 5.8%, respectively, of the patients in group A, whereas grade 1 
reductions occurred in 2.5% of the patients in group B. 
CONCLUSIONS: In previously untreated patients with HCV genotype 1 infection and no 
cirrhosis, a 12-week multitargeted regimen of ABT-450/r-ombitasvir and dasabuvir with ribavirin 
was highly effective and was associated with a low rate of treatment discontinuation. (Funded by 
AbbVie; SAPPHIRE-I ClinicalTrials.gov number, NCT01716585.). 
 
 
Patients with HCV cirrhosis are priority candidates for antiviral treatment, due to the high 
expected rate of progression to liver decompensation and eventually to death [1]. Interferon 
(IFN)-based dual or triple therapy with 1st generation protease inhibitors is poorly tolerated and 
has modest efficacy, especially in patients with marginally compensated or decompensated 
disease [2]. CUPIC, a large expanded access French program has shown in fact that low 
baseline albumin level (ie <35 g/L) combined with low platelet counts (ie <100,000/mm ) predict 
an unfavourable on-treatment course, with a higher risk of decompensation, infections and 
death, together with a low chance of HCV clearance [3]. 
 As the field moves rapidly to IFN-free regimen combining direct-acting antivirals (DAAs) 
which target multiple viral sites (NS3/4a protease, NS5B polymerase and NS5A replication 
complex), SVR rates beyond 90% are expected in non-cirrhotic patients, regardless of previous 
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response to IFN, with 8-12 weeks of therapy and with an excellent tolerability profile [4]. 
Notwithstanding the major clinical need of cirrhotics, most IFN-free trials up to now have 
excluded patients with cirrhosis or enrolled only a modest proportion (10 to 20%) of cirrhotics 
with well- compensated disease [5-7], thus negating the clinicians the information needed to 
treat those patients already bordering on the verge of decompensation. 
 Our comment deals with a recently published phase III trial (Turquoise-II) with ABT-450/r, 
ombitasvir, dasabuvir and ribavirin based regimen, performed exclusively in patients with GT1 
HCV cirrhosis ranging from well to marginally compensated disease [8]. This phase III trial was 
performed as a global, multi-center, randomized, open-label study including 380 patients with 
cirrhosis in Child-Pugh class A5 to A6 randomly assigned to receive either 12 or 24 weeks of 
treatment with ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of 
ritonavir, and 25 mg of ombitasvir), dasabuvir (250 mg twice daily), and ribavirin administered 
according to body weight (Figure 1A). Cirrhosis was documented by liver biopsy (Metavir score 
>3 or Ishak score >4) or FibroScan result (≥14.6 kPa within 6 months before screening or during 
screening). Interestingly, key eligibility criteria were a platelet count of 60,000 /mm or more, a 
serum albumin level of 2.8 g/dl or more, a total bilirubin level of less than 3 mg/dl, which makes 
us think that some patients actually belonged to Child-Pugh B7 class. 
 Patients achieved sustained virologic response rates 12 weeks post-treatment (SVR12) 
of 91.8 percent and 95.9 percent in the 12-week and 24-week treatment arms, respectively 
(Figure 1B). Patients in the study were either naïves or treatment- experienced (failed previous 
treatment with pegylated (PEG)-IFN and RBV)(Figure 1C). A prior null response and infection 
with HCV subgenotype 1a were associated with a lower likelihood of a SVR. Genotype 1a with 
history of null response were the predictors of non SVR in multivariate analysis, and that for 
platelets and albumin there was a non significant trend, with indeed an excellent chance to cure 
in this population. Interestingly, for patients with low platelets (< 109/L) reflecting portal 
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hypertension and/or those with low albumin (< 35 g/l) reflecting decreased hepatic function, have 
a high chance to cure, even though their absolute number is limited (Figure 1D). We do not have 
the precise result in patients who met these criteria (but the number of patients is probably 
limited). 
 Discontinuation rates due to adverse events were 1.9 percent (four patients) and 2.3 
percent (four patients) in the 12-week and 24-week arms, respectively. The most commonly 
reported adverse events (>10 percent in either arm) were fatigue, headache, nausea, pruritus, 
insomnia, diarrhea, asthenia, rash, cough, irritability, anemia and dyspnea. On-treatment 
virologic failure occurred in one patient (0.5 percent) in the 12-week arm and three patients (1.7 
percent) in the 24-week arm. In addition, 12 patients (5.9 percent) in the 12-week arm and one 
patient (0.6 percent) in the 24-week arm experienced relapse within 12 weeks post-treatment. 
 So, what have we learned from Turquoise-II study ? 
 First, a regimen with high efficacy in a population previously defined as « difficult to cure 
»: a 12 or 24 weeks of treatment with coformulated ABT-450/r–ombitasvir and dasabuvir, 
administered with ribavirin, resulted in high rates of SVR in patients with HCV compensated 
cirrhosis. Notably, approximately 15% of the study population had platelet counts that were 
clinically suggestive of portal hypertension. The overall efficacy of 12-week and 24-week 
treatment did not differ significantly (91.8% and 95.9%, respectively). Patients with HCV 
genotype 1a infection and a null response to prior PegIFN–ribavirin treatment might benefit from 
a 24 weeks treatment duration. In the most severe patients, again those with low platelets (< 
109/L) (SVR=88% for 12 weeks vs 97% for 24 weeks) and those with low albumin; the ideal 
duration of treatment remains unkown (12 vs 24 weeks). 
 Second, a regimen well-tolerated in this specific population. The majority of adverse 
events were mild or moderate in severity, with few events occurring more frequently in the 24-
week group than in the 12-week group. Serious adverse events occurred in 5.5% of all patients, 
with similar rates in each group, and few patients  discontinued the study treatment because of 
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adverse events (2.1% overall). Declines in the hemoglobin level of grade 2 or higher occurred in 
7.2% of patients in the 12- week group and in 11.0% of patients in the 24-week group. Declines 
in the hemoglobin level were successfully managed with modifications in the ribavirin dose, 
without a negative effect on the rate of SVR. Elevations in indirect bilirubin with this regimen are 
probably related to ribavirin-associated hemolysis, along with inhibition of the bilirubin 
transporter OATP1B1 by ABT-450 (protease inhibitors). Elevated bilirubin levels did not lead to 
treatment discontinuation, were not associated with elevations in the alanine aminotransferase 
level, and resolved to baseline levels during the post-treatment period. 
 What are the gaps to fill ? what the ideal study should perform ? 
 (1) Eligibility criteria should be more precisely defined to include more patients with portal 
hypertension (oesophageal varices, low platelet count) liver insufficiency (low albumin), Child-
Pugh A to B7, and/or compensated cirrhosis who presented previous decompensation (ascites 
or bleeding). A better definition and phenotyping of eligibility criteria should be outlined since 
significant proportion of patients with elasticity higher than 14.8 kPa might have bridging fibrosis 
(F3) without cirrhosis. To avoid unexpected issues with salvage therapy, well-designed studies 
in Child Pugh A to B7 and kidney dysfunction should be performed. In our opinion, patients with 
concurrent small hepato-cellular (HCC) and/or candidates to liver transplantation should be 
included. 
 (2) Long-term follow-up will be mandatory to demonstrate cirrhosis reversibility, portal 
hypertension reduction, HCC reduction and finally reduction of liver or not related mortality.  
 (3) These excellent results, however, should be confirmed in large number of patients 
with predictors of non response : in particular in patients with genotype 1a and previous non 
response and with more advanced cirrhosis. In European countries (specially southern and 
eastern europe) HCV genotype 1b is the most prevalent. 
 (4) Finally, do we need ribavirin in this difficult-to-treat population, given the excellent 
results of this combination and the adverse events related to ribavirin ? We will need to 
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investigate if ribavirin is necessary. 
 In conclusion, this large phase III study showed excellent results in term of efficacy and 
safety profile in GT1 HCV cirrhotic patients, in some cases bordering on decompensation. 
Several issues are still to be filled. We will need available IFN-free regimen for decompensated 
cirrhosis and a major issue will be access treatment. Phase III data in patients with cirrhosis and 
other HCV genotypes, such as Genotype 3 and 4, are clearly also an unfulfilled need [9]. While 
we have to congratulate this important addition to current knowldege, some caution and more 
importantly “real life” dataset are still needed, specially regarding safety and drug-drug 
interactions. 
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Fig. 1. Turquoise-II: trial design and results. (A) Trial Design. This is an open-label phase 3 
trial involving previously untreated and previously treated adults with HCV genotype 1 infection 
and compensated cirrhosis. 380 patients with Child-Pugh class A cirrhosis were randomly 
assigned to receive either 12 or 24 weeks of treatment with ABT-450/r-ombitasvir (at a once-
daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir (250 
mg twice daily), and ribavirin administered according to body weight. (B) Main results. Patients 
achieved SVR12 of 91.8 percent and 95.9 percent in the 12-week and 24-week treatment arms, 
respectively (no statistical difference). (C) Results: SVR12 Rates by Prior Treatment Response in 
HCV Subtype 1a. Among patients with HCV genotype 1a infection and a prior null response, 39 
of 42 patients in the 24-week group had a SVR12 (92.9% [95% CI, 85.1 to 100]), as compared 
with 40 of 50 patients in the 12-week group (80.0% [95% CI, 68.9 to 91.1]). (D) Results: ITT 
SVR12 rates by surrogates of portal hypertension and hepatic function.  
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